Actio Biosciences

Actio Biosciences is a private, preclinical-stage biotech pioneering a 'Rare-to-Common' drug development strategy. The company uses human genetic insights from monogenic rare diseases to identify and validate high-confidence drug targets, aiming to de-risk development and expand therapies into broader common disease populations. Its lead program, ABS-1230, is a selective inhibitor of KCNT1 for epilepsy disorders, with recent preclinical data showing significant seizure reduction. Actio's approach positions it at the intersection of precision medicine and scalable therapeutic development.

Integrated genetics-led discovery platform that starts with monogenic rare diseases to identify and validate drug targets, then leverages insights to de-risk and guide expansion into common diseases with shared biology.

Actio competes with other genetics-driven biotechs (e.g., Maze Therapeutics, BridgeBio affiliates) and large pharma precision medicine initiatives. Its differentiation lies in the explicit operational strategy of starting with rare diseases to de-risk common disease expansion, rather than mining common disease genetics directly.